 A message from Sideways Frequency |
| BioStem Technologies (BSEM): Record Revenues, Breakthrough Clinical Results, and Nasdaq Ambitions Position This MedTech Powerhouse for Explosive Growth! A Rapidly Growing MedTech Innovator for Your Radar. Peer-Reviewed Study in the International Journal of Tissue Repair Validates BioRetain®’s Superior Healing Results, Nearly Doubling Success Rates in Chronic Wound Patients! Greetings, All. The MedTech sector — where medicine meets cutting-edge technology — is one of the fastest-growing and most resilient industries in today’s market. As global healthcare spending rises and populations age, demand for advanced medical solutions continues to surge. From AI-driven diagnostics to regenerative therapies that heal rather than replace, MedTech innovations are transforming how diseases and injuries are treated worldwide. What makes this space especially compelling for investors is its combination of innovation, scalability, and defensiveness. Even during economic slowdowns, healthcare spending tends to remain strong, and MedTech companies often operate in markets that are both mission-critical and underpenetrated. This is where BioStem Technologies (OTC: BSEM) truly stands apart. While many MedTech firms are still in the conceptual or pre-commercial stage, BSEM is already profitable, reporting record revenues, expanding its clinical pipeline, and achieving peer-reviewed validation of its technology. Unlike many competitors, BSEM has FDA-registered, AATB-accredited facilities, a growing patent portfolio, and national reimbursement through Medicare, which dramatically increases accessibility and adoption. These achievements not only validate BioStem’s science—they create powerful economic barriers to entry. Highlights…. BSEM achieved record revenues in 2024 and continues to accelerate through 2025 with remarkable financial momentum. In its preliminary Q2 2025 results, BSEM reported $49.3 million in net revenue, $2.5 million in positive adjusted EBITDA (marking its sixth straight profitable quarter), and a cash balance of $30.8 million — underscoring strong operational performance and financial discipline. With a $25.50 Zacks Small Cap Research price target, BSEM stands out as a high-growth opportunity in the MedTech space. Its innovative approach to regenerative wound care, combined with rising investor and physician adoption, is setting the stage for sustained growth — and potential uplist to Nasdaq in the near term. Breakthrough Clinical Results Published in the International Journal of Tissue Repair A pivotal moment for BSEM came with the publication of its groundbreaking clinical trial in the International Journal of Tissue Repair. The peer-reviewed study evaluated the company’s proprietary BioRetain® amnion chorion allograft in patients suffering from non-healing diabetic foot ulcers (DFUs) — one of the most challenging and costly chronic conditions in modern medicine. The results were extraordinary:
Dr. Bert Slade, Chairman of BioStem’s Medical Advisory Board, called the results “strong evidence of treatment benefit,” reinforcing BioStem’s leadership in regenerative tissue technology. These findings not only validate the company’s proprietary BioRetain® process but also highlight its potential to transform the $27 billion global wound care market. Big Vision, Real Impact, and National Recognition Adding to its momentum, BSEM CEO Jason Matuszewski was named EY Entrepreneur of the Year 2025 (Florida) — a prestigious recognition that celebrates innovation, leadership, and long-term impact. Under his direction, BSEM has evolved from an early-stage biotech innovator into a profitable, fast-scaling MedTech company with a growing national footprint. The company’s mission — “to discover, develop, and produce the most effective regenerative medicine products in the world” — is being realized through its BioRetain®-based product suite, including Vendaje™, Vendaje AC™, Vendaje Optic™, and AmnioWrap2™, all processed at BioStem’s FDA-registered and AATB-accredited facility in Pompano Beach, Florida. Next Up: Nasdaq Uplisting and Institutional Access BSEM has officially filed with the SEC under the Securities Exchange Act of 1934, a key milestone toward its Nasdaq uplisting. Once complete, this move will significantly increase liquidity, attract institutional investors, and enhance visibility among global MedTech peers. Why BSEM Deserves a Place on Your Radar ✔ Peer-reviewed clinical validation proving BioRetain®’s superiority in chronic wound healing The Bottom Line With a growing product portfolio, published clinical evidence, and powerful financial momentum, BioStem Technologies (BSEM) is positioned at the forefront of a regenerative medicine revolution. As the company scales operations and prepares for a potential Nasdaq listing, BioStem stands out as one of the most exciting, high-growth MedTech opportunities of 2025 — blending strong science, profitability, and purpose-driven innovation. |
| This message is a paid advertisement for BioStem Technologies Inc. (OTC: BSEM) from Sideways Frequency. Schaeffer’s Investment Research Inc. receives a fixed fee for each subscriber that clicks on a link in this email. Other than the compensation received for this advertisement sent to subscribers, Schaeffer’s Investment Research Inc. and its principals are not affiliated with BioStem Technologies Inc. (OTC: BSEM). Schaeffer’s Investment Research Inc. and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither Schaeffer’s Investment Research Inc. nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Schaeffer’s Investment Research Inc. to buy or sell any security. Schaeffer’s Investment Research Inc. has not evaluated the accuracy of any claims made in this advertisement. Schaeffer’s Investment Research Inc. recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding BioStem Technologies Inc. (OTC: BSEM) on BioStem Technologies Inc. (OTC: BSEM) website for additional information. To stop receiving these emails, unsubscribe. |
Post a Comment
Post a Comment